Datapoint: Horizon Snags Gout Label Expansion for Krystexxa

The FDA on July 8 approved a label expansion for Horizon Therapeutics’ Krystexxa. The injectable, in combination with methotrexate, will be the first treatment available for uncontrolled gout in patients whose symptoms have not responded to other therapies. The drug was first approved in 2010. For the treatment of gouty arthritis, Krystexxa currently holds covered or better status for 57% of all insured lives under the pharmacy benefit. Krystexxa is not covered for 34% of lives.

Source: MMIT Analytics, as of 7/13/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: New Startup Insurer to Expand to Six More States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: FDA Approves Lilly’s Interchangeable Insulin

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today